Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Britain Courts Anthropic Amid US Defense Department Dispute 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
WALTHAM, Mass., Aug. 31, 2016 -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will present at the 18th Annual Rodman & Renshaw Global Investment Conference on Monday, September 12, 2016 at 11:40 AM EDT. The conference is sponsored by H.C. Wainwright & Co., LLC., and will be held September 11-13, 2016 at the Lotte New York Palace Hotel in New York City.
This presentation will be webcast live and may be accessed by visiting the Investor Relations section of Histogenics’ website at www.histogenics.com. The webcast will be archived and available on Histogenics’ website for 45 days following the conference.
About Histogenics Corporation
Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, is currently in Phase 3 clinical development. NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells. Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year. NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options. For more information, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
